Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
STERIS from Watermaal-Bosvoorde, company number BE0440556578, closed financial year 2025 with a result of € 504,676 after tax. For that financial year STERIS recorded revenue of € 14.1 million and equity of € 1.5 million. Compared with financial year 2024, the result moved from € 264,328 to € 504,676. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on November 26, 2025.
€ 1.5 million
▲ 50% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 504,676
▲ 91% vs 2024
Profit after tax over the fiscal year.
€ 4.2 million
▲ 111% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.2 million.
People and assets in 2025
16.2
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.3 million
▲ 27% vs 2024
€ 139,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,265
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6.1 million
▲ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 165 days on average.
€ 723,258
▼ 24% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 9,233,868 | € 10,896,632 | € 14,244,438 | € 14,079,958 | ▼ 1% |
| Profit after taxes | € 250,316 | € 637,621 | € 264,328 | € 504,676 | ▲ 91% |
| Equity | € 1,608,805 | € 2,246,426 | € 1,010,632 | € 1,515,308 | ▲ 50% |
| Total debts | € 5,738,661 | € 6,154,076 | € 11,070,913 | € 11,688,692 | ▲ 6% |
| Cash | € 2,884,220 | € 3,250,256 | € 2,012,551 | € 4,243,472 | ▲ 111% |
| Retained profit | € 1,305,135 | € 1,942,757 | € 706,962 | € 1,211,638 | ▲ 71% |
| Dividend | € 4,500,367 | € 0 | € 1,500,122 | € 0 | ▼ 100% |
| Balance sheet total | € 7,347,465 | € 8,400,503 | € 12,081,545 | € 13,204,000 | ▲ 9% |
| Employees (FTE) | 8.1 | 9.2 | 16 | 16.2 | ▲ 0.2 |
Key figures of STERIS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to STERIS?
What happened at STERIS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Michael Joseph TOKICH stepped down as director. NBB
- Allan ROWLEY stepped down as director. NBB
- John Patrick UBBING stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 504,676 (▲ 91% vs 2024). filed late Source: NBB ↗
- Michael Joseph TOKICH became a director. NBB
- Allan ROWLEY became a director. NBB
- Ronald E. SNYDER stepped down as director. NBB
- John Patrick UBBING became a director. NBB
In short
From € 250,316 profit in 2022 to € 504,676 profit in 2025.
Paid € 670,578 in corporate taxes since 2022.
Best year ever: 2023, with € 637,621 profit.
Paid out € 6 million in dividends to the owners in total.
A new publication or filing at STERIS? We notify you, reason included.
Follow STERISDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by STERIS HOLDING SA (100%) and STERIS DEUTSCHLAND SPRL (0%).
Directors
According to the 2025 annual accounts
John Patrick UBBING
Director
since 2022 · until 2028
Ronald E. SNYDER
Director
since 2018 · until 2024
Allan ROWLEY
Director
since 2024 · until 2029
Michael Joseph TOKICH
Director
since 2024 · until 2030
Shareholders
STERIS HOLDING SA
100%
STERIS DEUTSCHLAND SPRL
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Terhulpsesteenweg 177 box 11
1170 Watermaal-Bosvoorde
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Euroconseils
€ -776 gross margin · 2025
Chanic
€ 126,443 gross margin · 2025
VISHA
€ 164,650 gross margin · 2025
International Beverages Corporation
Pro Familia
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0440.556.578
- VAT number
- BE 0440.556.578
- Registered office
- Terhulpsesteenweg 177 bus 11, 1170 Watermaal-Bosvoorde
- Names & denominations
- STERIS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 April 1990
- Peppol
- Active · Active since 15 Sept 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten